FibroBiologics, Inc.

Contributing Author

Recent Articles by FibroBiologics, Inc.

Feb-10	FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University FBLG +6.24% GlobeNewswire
Feb-05	FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia FBLG -9.20% GlobeNewswire
Jan-20	FibroBiologics to Present at the DealFlow Discovery Conference FBLG GlobeNewswire
Jan-07	FibroBiologics CEO Issues Letter to Shareholders FBLG +32.27% GlobeNewswire
Jan-06	FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference FBLG +6.78% GlobeNewswire
Jan-05	FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease FBLG GlobeNewswire
Dec-31	FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis FBLG -7.03% GlobeNewswire
Dec-16	FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules FBLG +14.53% FBLG -8.44% GlobeNewswire
Dec-15	FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules FBLG -33.06% GlobeNewswire
Dec-10	FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions FBLG +12.82% GlobeNewswire
Nov-26	FibroBiologics Announces Payoff of Outstanding Debt FBLG GlobeNewswire
Nov-25	FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules FBLG GlobeNewswire
Nov-24	FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules FBLG -23.53% GlobeNewswire
Nov-20	FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers FBLG -5.78% GlobeNewswire
Nov-19	FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules FBLG -5.78% GlobeNewswire
Nov-19	FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules FBLG GlobeNewswire
Oct-31	FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update FBLG GlobeNewswire
Oct-24	FibroBiologics to Present at Bio-Europe 2025 FBLG +6.28% GlobeNewswire
Oct-14	FibroBiologics to Present at the 2025 ThinkEquity Conference FBLG GlobeNewswire
Sep-23	FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa FBLG GlobeNewswire
Sep-12	FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies FBLG GlobeNewswire
Sep-11	FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment FBLG GlobeNewswire
Sep-10	FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies FBLG GlobeNewswire
Aug-27	FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference FBLG GlobeNewswire
Jul-31	FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update FBLG GlobeNewswire
Jul-28	FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications FBLG GlobeNewswire
Jul-11	FibroBiologics to Present at the Advanced Wound Care Summit USA FBLG GlobeNewswire
Jul-09	FibroBiologics Confirms Ability to Manufacture CybroCell for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank FBLG +9.04% GlobeNewswire
Jul-07	FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 FBLG GlobeNewswire
Jun-16	FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing FBLG -5.48% FBLG GlobeNewswire
Jun-16	FibroBiologics to Present at the BIO International Convention 2025 FBLG GlobeNewswire
Jun-09	FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer FBLG GlobeNewswire
May-16	FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting FBLG -8.42% GlobeNewswire
May-14	FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update FBLG +22.67% FBLG GlobeNewswire

FibroBiologics, Inc.

Recent Articles by FibroBiologics, Inc.

Upgrade your FINVIZ experience